Clinical trials - Press Releases

Date	Title	Company
14-Dec-2023	ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)	ADC Therapeutics
14-Dec-2023	1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors	1ST Biotherapeutics
14-Dec-2023	Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research	Centricity Research
13-Dec-2023	SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier® Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata	SiSaf
11-Dec-2023	New Data Presented at ASH from the Phase 3 GLOW Study Show Fixed-Duration, First-Line Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated an Overall Survival Rate of More Than 84 Percent at 54 Months in Patients with Chronic Lymphocytic Leukaemia	Jassen
11-Dec-2023	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	ImmunoGen
08-Dec-2023	PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023	PureTech
08-Dec-2023	Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)	Vesper Bio
08-Dec-2023	2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial	2cureX
05-Dec-2023	Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board	Thermosome GmbH
30-Nov-2023	PHARMANOVIA STRENGTHENS MEDICAL AFFAIRS TEAM WITH KEY APPOINTMENTS TO SUPPORT GLOBAL GROWTH	Pharmanovia
29-Nov-2023	Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy	Qnovia
29-Nov-2023	Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma	Valo Therapeutics
28-Nov-2023	Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus	Astraveus SAS
28-Nov-2023	NICE endorses only approved treatment for ultra-rare Wolman disease for children diagnosed under the age of two: Interview Opportunity	National Institute for Health and Care Excellence (NICE)
28-Nov-2023	National call for volunteers to test ground-breaking psychedelic treatments for mental health conditions	Clerkenwell Health
28-Nov-2023	ACG showcases a concept of a next generation capsule filling machine- AF330 at CPHI and PMEC 2023	ACG
28-Nov-2023	Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID	Revvity
28-Nov-2023	HBK’s Suzhou Production Site Achieves ISO 13485 Certification	HBK
28-Nov-2023	Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept	Evaxion Biotech A/S